Pfizer is a member of SCDAA’s SCD C.A.R.E.S. Consortium.
“Pfizer is working to discover and develop treatments for people living with serious blood disorders, including sickle cell disease (SCD). We recognize that people living with SCD need solutions for disease symptoms as well as potential treatment options.
Our deep market knowledge and insights we have built over three decades in rare hematology along with our leading scientific and clinical capabilities has the potential to accelerate innovation and bring potential breakthrough treatments to these communities as quickly as possible.
Our goal is to transform the treatment of SCD and help address the urgent needs of the community. Our mission is driven by the historical lack of understanding and attention given to SCD. Although the fundamental cause of SCD has been understood for decades, therapeutic innovation and access to care has significantly lagged.
In line with our value of equity, Pfizer has long been committed to addressing the underserved needs of the sickle cell community, and we are excited to now have an opportunity to transform the lives of patients with this pipeline of potential medicines.”
Learn more about Pfizer’s research.
Featured Clinical Trials
- A Study in Adult and Pediatric Participants With Sickle Cell Disease (SCD)
- A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
- A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
- Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease (HOPE Kids)
Follow Pfizer on social media
 |
 |
 |
 |
The SCD C.A.R.E.S. Consortium aims to change the perception of clinical trials and increase the participation of sickle cell patients in clinical trials to ultimately provide more therapies to the SCD community. Together, the consortium works together to educate and encourage more trial participation while providing opportunities and better options for the treatment of sickle cell disease.
